

Session ID	Session Title	Session Type	Presenter 1	Presenter 2	Presenter 3	Presenter 4	Presenter 5	Presenter 6	Presenter 7	Presenter 8	Presenter 9																													
C01	Best Practices in Sleep Medicine 2009	8-hour Postgraduate Course	Michael Littner, MD Conflicts: None	Tedolfo Lee-Chong, MD Conflicts: None	Alon Y. Avidan, MD, MPH Speakers' Bureau: Takeda Pharmaceuticals, Boehringer Ingelheim, Sepracor, Inc., Cephalon, Inc. Consultants: 1. Vaughn BV and D'Cruz, O.N., Parasomnias and Other Nocturnal Events. American Academy of Neurology Continuum: Living learning in neurology. Sleep Disorders, 2007; 13(3): p. 225-247. 2. Giglio, P., N. Undeva, and J.P. Spire. The primary parasomnias. A review for neurologists. Neurologist, 2005; 11(2): p. 58-73. 3. Ferris-Strambi, L., et al. REM sleep behaviour disorder. Neuro Sci, 2005; 26 Suppl 3: p. s186-92. 4. Mahowald, M.W., M.C. Borremann, and C.H. Schenck. Parasomnias. Semin Neurol, 2004; 24(3): p. 283-92. 5. Bazzi, C.W., et al. Nocturnal seizures. Semin Neurol, 2004; 24(3): p. 293-300.	Presenter 4 Charlene Gamaldo, MD Investigation Device/Drug: RXP1109806 G-SK Phase II Trial Site Citations: 1. Mov Disord, 2008 Dec 15;23(16):2267-302. Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice. Trenkwalder C, Hening WA, Montagna P, Oertel WH, Allen RP, Walters AS, Costa J, Slasny-Kolster K, Sampaio C, 2. Sleep, 2004 May 1;27(5):674-9. Practice parameters for the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Littner MK, Kushida C, Anderson WA, Bailey D, Berry RB, Hirshkowitz M, Kagan S, Kramar M, Lee-Chong T, Lu KK, Loube DL, Morgenthaler T, Vite M, Standards of Practice Committee of the American Academy of Sleep Medicine. 3. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute, Garcia-Borreguero D, Allen RP, Kohnen R, Hogg B, Trenkwalder C, Oertel W, Hening WA, Paulus R, Ryg D, Walters A, Winkelmann J, Earley CJ. International Restless Legs Syndrome Study Group. Sleep Med, 2007 Aug;8(5):520-30. Epub 2007 Jun 1. Erratum in Sleep Med, 2007 Nov;8(7-8):768. Earley, Christopher J	Presenter 5 Phyllis C. Zee, MD, PhD Consultant: Takeda, Sanofi-Aventis Grant/Research Support: Takeda Citations: 1. Barion A, Zee PC. A clinical approach to circadian rhythm sleep disorders. Sleep Med, 2007 Sep;8(9):956-77. 2. Riemersma-van der Lek RF, Swaab DF, Tweek J, Hol EM, Hoogendijk WJ, Van Someren EJ. Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a randomized controlled trial. JAMA, 2006 Jun 14;295(23):2842-55. 3. Dowling GA, Burr RL. Van Someren EJ, Hubbard EM, Luxenberg JS, Mastick J, Cooper BA. Melatonin and bright-light treatment for rest-awake melatonin and nonmelatonin bright light. Archives of Clinical Endocrinology and Metabolism 91:54-59. 4. Wang Weigang S, Samir S, Zhang J. The effects of ramelteon in a first-night model of transient insomnia. Sleep Med, 2008 Aug 6.	Presenter 6 Samuel Kuna, MD Salary: Responics, Inc. Grant/Research Support: Responics, Inc. Other Financial/Material Support: Responics, Inc. Citations: 1. American Academy of Sleep Medicine Report. Practice parameters for the use of continuous and bilevel positive airway pressure devices to treat adult patients with sleep-related breathing disorders. Sleep 2006;29:375-93. 2. Collop NA, Anderson WM, Boehlcke B, et al. Clinical guidelines for the use of unattended portable monitors in the diagnosis of obstructive sleep apnea in adult patients. Portable Monitoring Task Force of the American Academy of Sleep Medicine. J Clin Sleep Med 2007;15:737-47. 3. Kushida CA, Chrousos A, Berry RB, Brown LK, Guzal D, Iber C, Parthasarathy S, Quan SF, Rowley JA. Positive Airway Pressure Titration Task Force. American Academy of Sleep Medicine. Clinical guidelines for the manual titration of positive airway pressure in patients with obstructive sleep apnea. J Clin Sleep Med, 2008 Apr 15;4(2):157-71.	Presenter 7 Carole Marcus, MBChB Grant/Research Support: Responics Citations: 1. Schechter MS. Technical report: diagnosis and management of childhood obstructive sleep apnea syndrome. Pediatrics 2002;109:E69. 2. American Academy of Pediatrics. Clinical practice guidelines: diagnosis and management of childhood obstructive sleep apnea syndrome. Pediatrics 2002;109:704-12. 3. The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology, and Technical Specifications. Iber C, editor. 2007. American Academy of Sleep Medicine	Presenter 8 Jennifer Martin, PhD Conflicts: None	Presenter 9 Emmanuel Mignot, MD, PhD Consultant: Eli Lilly, Actelion, Jazz Pharmaceuticals Grant/Research Support: Responics, ResMed Citations: 1. Capasso R, Mignot E (2008) Diagnosis and Management of Common Sleep Disorders: An Overview for the Psychiatrist. European Psychiatric Review, 2008; 16; 2. Bourgon P, Zatz J, Mignot E (2008). Hypocretin in sleep and neurological disorders. Lancet Neurol. 7(7):649-62. Review. Erratum in Lancet Neurol. 7(8):771. 3. Dauvilliers Y, Arnulf I, Mignot E (2007). Narcolepsy with cataplexy. Lancet. 369(9550): 499-511.																													
C02	Diagnosis and Treatment of Circadian Rhythm Sleep Disorders	8-hour Postgraduate Course	R. Robert Auger, MD Other Financial/Material Support: Editorial Consultant, WPIR Citations: 1. Auger RR, Auger RR, Carskadon MA, Wright KP Jr, Vite M, Zhdanova IV. Circadian Rhythm Sleep Disorders: Part I. Basic Principles, Shift Work and Jet Lag. An American Academy of Sleep Medicine Review. Sleep 2007; 30:1456-1479. 2. Duffy JF, Wright KP Jr. Entrainment of the Human Circadian System by Light. Journal of Biological Rhythms, 2005; 28: 326-338. 3. Wright KP Jr., Rogers NL. Endogenous Versus Exogenous Effects of Melatonin. In SR Pandi-Neural and DP Cardinali (Eds): Melatonin: from Molecules to Therapy. Nova Science Publishers, Inc. Hauppauge, NY, 2007; 547-569.	Kenneth P. Wright Jr., PhD Other Financial/Material Support: Axon Labs, Inc., Cephalon, Inc., Novartis, Takeda Pharmaceuticals North America Grant/Research Support: Cephalon, Inc., Takeda Pharmaceuticals North America Stock/Shareholder: Axon Labs, Inc. Citations: 1. Sakai R, Avidan Y, Auger RR, Carskadon MA, Wright KP Jr, Vite M, Zhdanova IV. Circadian Rhythm Sleep Disorders: Part I. Basic Principles, Shift Work and Jet Lag. An American Academy of Sleep Medicine Review. Sleep 2007; 30:1456-1479. 2. Duffy JF, Wright KP Jr. Entrainment of the Human Circadian System by Light. Journal of Biological Rhythms, 2005; 28: 326-338. 3. Wright KP Jr., Rogers NL. Endogenous Versus Exogenous Effects of Melatonin. In SR Pandi-Neural and DP Cardinali (Eds): Melatonin: from Molecules to Therapy. Nova Science Publishers, Inc. Hauppauge, NY, 2007; 547-569.	James K. Wyatt, PhD Consultant: Takeda Global Research & Development Citations: 1. Richardson SG, Zee PC, Wang Weigang S, Rodrigues L, Peng X. Circadian phase-shifting effects of repeated ramelteon administration in healthy adults. J Clin Sleep Med, 2008 Oct 15;4(5):456-61. 2. Sateia MJ, Kirby Long P, Taylor JL. Efficacy and clinical safety of ramelteon: an evidence-based review. Sleep Med Review, 2008 Aug;12(4):319-32. 3. Zammitt G, Schwartz H, Roth T, Wang Weigang S, Samir S, Zhang J. The effects of ramelteon in a first-night model of transient insomnia. Sleep Med, 2008 Aug 6.	Helen J. Burgess, PhD Other Financial/Material Support: Editorial Consultant, WPIER Citations: 1. Daan, S, and A. J. Lewy (1984). Scheduled exposure to daylight: a potential strategy to reduce jet lag. J Biol Rhythms 1: 299-323. 2. Revell VL, H. J. Burgess, et al. (2006). Advancing human circadian rhythms with afternoon melatonin and morning bright light. Archives of Clinical Endocrinology and Metabolism 91:54-59. 3. Wang Weigang S, Samir S, Zhang J. The effects of ramelteon in a first-night model of transient insomnia. Sleep Med, 2008 Aug 6.	Phyllis C. Zee, MD, PhD Consultant: Takeda, Sanofi-Aventis Grant/Research Support: Takeda Citations: 1. Barion A, Zee PC. A clinical approach to circadian rhythm sleep disorders. Sleep Med, 2007 Sep;8(9):956-77. 2. Riemersma-van der Lek RF, Swaab DF, Tweek J, Hol EM, Hoogendijk WJ, Van Someren EJ. Effect of bright light and melatonin on cognitive and noncognitive function in elderly residents of group care facilities: a randomized controlled trial. JAMA, 2006 Jun 14;295(23):2842-55. 3. Dowling GA, Burr RL, Van Someren EJ, Hubbard EM, Luxenberg JS, Mastick J, Cooper BA. Melatonin and bright-light treatment for rest-awake melatonin and nonmelatonin bright light. Archives of Clinical Endocrinology and Metabolism 91:54-59. 4. Wang Weigang S, Samir S, Zhang J. The effects of ramelteon in a first-night model of transient insomnia. Sleep Med, 2008 Aug 6.	David Gozal, MD Conflicts: None	Sigrd Veasey, MD Conflicts: None	Vasilevod Polotsky, MD, PhD Conflicts: None																														
C03	Inflammatory Mediators and Chronic Inflammation in Sleep Pathology	8-hour Postgraduate Course	Mark R. Opp, PhD Conflicts: None	Carole Marcus, MBChB Grant/Research Support: Responics Citations: 1. Schechter MS. Technical report: diagnosis and management of childhood obstructive sleep apnea syndrome. Pediatrics 2002;109:E69. 2. American Academy of Pediatrics. Clinical practice guidelines: diagnosis and management of childhood obstructive sleep apnea syndrome. Pediatrics 2002;109:704-12. 3. The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology, and Technical Specifications. Iber C, editor. 2007. American Academy of Sleep Medicine	Carole Marcus, MBChB Grant/Research Support: Responics Citations: 1. Schechter MS. Technical report: diagnosis and management of childhood obstructive sleep apnea syndrome. Pediatrics 2002;109:E69. 2. American Academy of Pediatrics. Clinical practice guidelines: diagnosis and management of childhood obstructive sleep apnea syndrome. Pediatrics 2002;109:704-12. 3. The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology, and Technical Specifications. Iber C, editor. 2007. American Academy of Sleep Medicine	Valerie Kirk, MD Conflicts: None	Cynthia Nichols, PhD Conflicts: None	Madeleine Grigg-Damberger, MD Stock/Shareholder: Galaxo-SmithKline, Phyllis Responics, Sanofi Aventis Speakers' Bureau: Responics Citations: 1. Kushida CA, Littner MR, Morgenthaler T et al. Practice parameters for the indications for polysomnography and related procedures: an update for 2005. Sleep 2005;28:499-521. 2. Guilleminau C, Palombini L, Pelayo R, Chervin RD. Sleep walking and sleep terrors in prepubertal children: what triggers them? Pediatrics 2003;111:e17-25. 3. Bazzi C, Walczak TS. Effects of sleep and sleep stage on epileptic and nonepileptic seizures. Epilepsia 1997;38:56-62.	Judith Owens, MD Grant/Research Support: Eli Lilly, Boehringer-Ingelheim Consultant: Takeda, Adrenex, Shire, Boehringer-Ingelheim, McNeil, Eli Lilly, Select Comfort Speakers' Bureau: Johnson and Johnson, Eli Lilly Citations: 1. Chervin RD, Archbold KH. Hyperarousal and polysomnographic findings in children evaluated for sleep disordered breathing. Sleep 24:319-320. 2. Goebel JL, et al. Sleep architecture and REM sleep measures in prepubertal children with attention deficit disorder with hyperactivity. Sleep 1983;6:91-101. 3. Hoban T. Assessment and treatment of disturbed sleep in attention deficit hyperactivity disorder. Expert Rev Neurother 2004;4:307-316.	David Gozal, MD Conflicts: None	Sigrd Veasey, MD Conflicts: None	Vasilevod Polotsky, MD, PhD Conflicts: None																												
C04	Pediatric Sleep Medicine: Approach to Diagnosis and Management	8-hour Postgraduate Course	Merrill S. Wise, MD Conflicts: None	Rachel Salata, MD Conflicts: None	Patrick Strolo Jr., MD Conflicts: None	Arthur Walker, MD Consultant: GSK, UCB Grant/Research Support: GSK Citations: 1. Onof, W. G. (2006). Methadone for sleep disturbances: a pilot study. Behav Res Ther, 2007 Mar;45(3):627-32. 2. Krawiec B, Hofffield M, Johnston Westbrook D (eds.). The Oxford Handbook of Behavioral Experiments. Oxford University Press: Oxford. 2. Harvey, A. G., Rev. M.J., Sharpley, A.J., Stronson, K., & Clark, D.M. (2007). An Open Trial of Cognitive Therapy for Chronic Insomnia. Behavior Research and Therapy, 45, 2491-2501.	Valerie Kirk, MD Conflicts: None	Cynthia Nichols, PhD Conflicts: None	Richard Allen, PhD Consultant: GSK, Pfizer, UCB, Neurogen Grant/Research Support: GSK Citations: 1. Earley, C. J., Hecker, D., & Allen, R. P. (2005). Repeated brief doses of oral prazosin provide supplemental treatment of restless legs syndrome. Sleep Med, 8(4): 301-306. 2. Earley, C.J., Hecker, D., Horvath A., Barker, P. B., & Allen, R. P. (2004). The treatment of severe restless legs syndrome: a randomized, double-blind, placebo-controlled trial. Lancet Neurol, 7(7): 595-604. 3. Trenkwalder, C., Heinig, F. A., Montagna, P., Oertel, W. H., Allen, R. P., Walters, A. S., et al. (2008). A randomized, double-blind, placebo-controlled trial of intravenous suvorelone in restless legs syndrome. Sleep Med.	Richard Allen, PhD Consultant: GSK, Pfizer, UCB, Neurogen Grant/Research Support: GSK Citations: 1. Earley, C. J., Hecker, D., & Allen, R. P. (2005). Repeated brief doses of oral prazosin provide supplemental treatment of restless legs syndrome. Sleep Med, 8(4): 301-306. 2. Earley, C.J., Hecker, D., Horvath A., Barker, P. B., & Allen, R. P. (2004). The treatment of severe restless legs syndrome: a randomized, double-blind, placebo-controlled trial. Lancet Neurol, 7(7): 595-604. 3. Trenkwalder, C., Heinig, F. A., Montagna, P., Oertel, W. H., Allen, R. P., Walters, A. S., et al. (2008). A randomized, double-blind, placebo-controlled trial of intravenous suvorelone in restless legs syndrome. Sleep Med.	Richard Allen, PhD Consultant: GSK, Pfizer, UCB, Neurogen Grant/Research Support: GSK Citations: 1. Earley, C. J., Hecker, D., & Allen, R. P. (2005). Repeated brief doses of oral prazosin provide supplemental treatment of restless legs syndrome. Sleep Med, 8(4): 301-306. 2. Earley, C.J., Hecker, D., Horvath A., Barker, P. B., & Allen, R. P. (2004). The treatment of severe restless legs syndrome: a randomized, double-blind, placebo-controlled trial. Lancet Neurol, 7(7): 595-604. 3. Trenkwalder, C., Heinig, F. A., Montagna, P., Oertel, W. H., Allen, R. P., Walters, A. S., et al. (2008). A randomized, double-blind, placebo-controlled trial of intravenous suvorelone in restless legs syndrome. Sleep Med.	Richard Allen, PhD Consultant: GSK, Pfizer, UCB, Neurogen Grant/Research Support: GSK Citations: 1. Earley, C. J., Hecker, D., & Allen, R. P. (2005). Repeated brief doses of oral prazosin provide supplemental treatment of restless legs syndrome. Sleep Med, 8(4): 301-306. 2. Earley, C.J., Hecker, D., Horvath A., Barker, P. B., & Allen, R. P. (2004). The treatment of severe restless legs syndrome: a randomized, double-blind, placebo-controlled trial. Lancet Neurol, 7(7): 595-604. 3. Trenkwalder, C., Heinig, F. A., Montagna, P., Oertel, W. H., Allen, R. P., Walters, A. S., et al. (2008). A randomized, double-blind, placebo-controlled trial of intravenous suvorelone in restless legs syndrome. Sleep Med.	Richard Allen, PhD Consultant: GSK, Pfizer, UCB, Neurogen Grant/Research Support: GSK Citations: 1. Earley, C. J., Hecker, D., & Allen, R. P. (2005). Repeated brief doses of oral prazosin provide supplemental treatment of restless legs syndrome. Sleep Med, 8(4): 301-306. 2. Earley, C.J., Hecker, D., Horvath A., Barker, P. B., & Allen, R. P. (2004). The treatment of severe restless legs syndrome: a randomized, double-blind, placebo-controlled trial. Lancet Neurol, 7(7): 595-604. 3. Trenkwalder, C., Heinig, F. A., Montagna, P., Oertel, W. H., Allen, R. P., Walters, A. S., et al. (2008). A randomized, double-blind, placebo-controlled trial of intravenous suvorelone in restless legs syndrome. Sleep Med.	Richard Allen, PhD Consultant: GSK, Pfizer, UCB, Neurogen Grant/Research Support: GSK Citations: 1. Earley, C. J., Hecker, D., & Allen, R. P. (2005). Repeated brief doses of oral prazosin provide supplemental treatment of restless legs syndrome. Sleep Med, 8(4): 301-306. 2. Earley, C.J., Hecker, D., Horvath A., Barker, P. B., & Allen, R. P. (2004). The treatment of severe restless legs syndrome: a randomized, double-blind, placebo-controlled trial. Lancet Neurol, 7(7): 595-604. 3. Trenkwalder, C., Heinig, F. A., Montagna, P., Oertel, W. H., Allen, R. P., Walters, A. S., et al. (2008). A randomized, double-blind, placebo-controlled trial of intravenous suvorelone in restless legs syndrome. Sleep Med.	Richard Allen, PhD Consultant: GSK, Pfizer, UCB, Neurogen Grant/Research Support: GSK Citations: 1. Earley, C. J., Hecker, D., & Allen, R. P. (2005). Repeated brief doses of oral prazosin provide supplemental treatment of restless legs syndrome. Sleep Med, 8(4): 301-306. 2. Earley, C.J., Hecker, D., Horvath A., Barker, P. B., & Allen, R. P. (2004). The treatment of severe restless legs syndrome: a randomized, double-blind, placebo-controlled trial. Lancet Neurol, 7(7): 595-604. 3. Trenkwalder, C., Heinig, F. A., Montagna, P., Oertel, W. H., Allen, R. P., Walters, A. S., et al. (2008). A randomized, double-blind, placebo-controlled trial of intravenous suvorelone in restless legs syndrome. Sleep Med.	Richard Allen, PhD Consultant: GSK, Pfizer, UCB, Neurogen Grant/Research Support: GSK Citations: 1. Earley, C. J., Hecker, D., & Allen, R. P. (2005). Repeated brief doses of oral prazosin provide supplemental treatment of restless legs syndrome. Sleep Med, 8(4): 301-306. 2. Earley, C.J., Hecker, D., Horvath A., Barker, P. B., & Allen, R. P. (2004). The treatment of severe restless legs syndrome: a randomized, double-blind, placebo-controlled trial. Lancet Neurol, 7(7): 595-604. 3. Trenkwalder, C., Heinig, F. A., Montagna, P., Oertel, W. H., Allen, R. P., Walters, A. S., et al. (2008). A randomized, double-blind, placebo-controlled trial of intravenous suvorelone in restless legs syndrome. Sleep Med.	Richard Allen, PhD Consultant: GSK, Pfizer, UCB, Neurogen Grant/Research Support: GSK Citations: 1. Earley, C. J., Hecker, D., & Allen, R. P. (2005). Repeated brief doses of oral prazosin provide supplemental treatment of restless legs syndrome. Sleep Med, 8(4): 301-306. 2. Earley, C.J., Hecker, D., Horvath A., Barker, P. B., & Allen, R. P. (2004). The treatment of severe restless legs syndrome: a randomized, double-blind, placebo-controlled trial. Lancet Neurol, 7(7): 595-604. 3. Trenkwalder, C., Heinig, F. A., Montagna, P., Oertel, W. H., Allen, R. P., Walters, A. S., et al. (2008). A randomized, double-blind, placebo-controlled trial of intravenous suvorelone in restless legs syndrome. Sleep Med.	Richard Allen, PhD Consultant: GSK, Pfizer, UCB, Neurogen Grant/Research Support: GSK Citations: 1. Earley, C. J., Hecker, D., & Allen, R. P. (2005). Repeated brief doses of oral prazosin provide supplemental treatment of restless legs syndrome. Sleep Med, 8(4): 301-306. 2. Earley, C.J., Hecker, D., Horvath A., Barker, P. B., & Allen, R. P. (2004). The treatment of severe restless legs syndrome: a randomized, double-blind, placebo-controlled trial. Lancet Neurol, 7(7): 595-604. 3. Trenkwalder, C., Heinig, F. A., Montagna, P., Oertel, W. H., Allen, R. P., Walters, A. S., et al. (2008). A randomized, double-blind, placebo-controlled trial of intravenous suvorelone in restless legs syndrome. Sleep Med.	Richard Allen, PhD Consultant: GSK, Pfizer, UCB, Neurogen Grant/Research Support: GSK Citations: 1. Earley, C. J., Hecker, D., & Allen, R. P. (2005). Repeated brief doses of oral prazosin provide supplemental treatment of restless legs syndrome. Sleep Med, 8(4): 301-306. 2. Earley, C.J., Hecker, D., Horvath A., Barker, P. B., & Allen, R. P. (2004). The treatment of severe restless legs syndrome: a randomized, double-blind, placebo-controlled trial. Lancet Neurol, 7(7): 595-604. 3. Trenkwalder, C., Heinig, F. A., Montagna, P., Oertel, W. H., Allen, R. P., Walters, A. S., et al. (2008). A randomized, double-blind, placebo-controlled trial of intravenous suvorelone in restless legs syndrome. Sleep Med.	Richard Allen, PhD Consultant: GSK, Pfizer, UCB, Neurogen Grant/Research Support: GSK Citations: 1. Earley, C. J., Hecker, D., & Allen, R. P. (2005). Repeated brief doses of oral prazosin provide supplemental treatment of restless legs syndrome. Sleep Med, 8(4): 301-306. 2. Earley, C.J., Hecker, D., Horvath A., Barker, P. B., & Allen, R. P. (2004). The treatment of severe restless legs syndrome: a randomized, double-blind, placebo-controlled trial. Lancet Neurol, 7(7): 595-604. 3. Trenkwalder, C., Heinig, F. A., Montagna, P., Oertel, W. H., Allen, R. P., Walters, A. S., et al. (2008). A randomized, double-blind, placebo-controlled trial of intravenous suvorelone in restless legs syndrome. Sleep Med.	Richard Allen, PhD Consultant: GSK, Pfizer, UCB, Neurogen Grant/Research Support: GSK Citations: 1. Earley, C. J., Hecker, D., & Allen, R. P. (2005). Repeated brief doses of oral prazosin provide supplemental treatment of restless legs syndrome. Sleep Med, 8(4): 301-306. 2. Earley, C.J., Hecker, D., Horvath A., Barker, P. B., & Allen, R. P. (2004). The treatment of severe restless legs syndrome: a randomized, double-blind, placebo-controlled trial. Lancet Neurol, 7(7): 595-604. 3. Trenkwalder, C., Heinig, F. A., Montagna, P., Oertel, W. H., Allen, R. P., Walters, A. S., et al. (2008). A randomized, double-blind, placebo-controlled trial of intravenous suvorelone in restless legs syndrome. Sleep Med.	Richard Allen, PhD Consultant: GSK, Pfizer, UCB, Neurogen Grant/Research Support: GSK Citations: 1. Earley, C. J., Hecker, D., & Allen, R. P. (2005). Repeated brief doses of oral prazosin provide supplemental treatment of restless legs syndrome. Sleep Med, 8(4): 301-306. 2. Earley, C.J., Hecker, D., Horvath A., Barker, P. B., & Allen, R. P. (2004). The treatment of severe restless legs syndrome: a randomized, double-blind, placebo-controlled trial. Lancet Neurol, 7(7): 595-604. 3. Trenkwalder, C., Heinig, F. A., Montagna, P., Oertel, W. H., Allen, R. P., Walters, A. S., et al. (2008). A randomized, double-blind, placebo-controlled trial of intravenous suvorelone in restless legs syndrome. Sleep Med.	Richard Allen, PhD Consultant: GSK, Pfizer, UCB, Neurogen Grant/Research Support: GSK Citations: 1. Earley, C. J., Hecker, D., & Allen, R. P. (2005). Repeated brief doses of oral prazosin provide supplemental treatment of restless legs syndrome. Sleep Med, 8(4): 301-306. 2. Earley, C.J., Hecker, D., Horvath A., Barker, P. B., & Allen, R. P. (2004). The treatment of severe restless legs syndrome: a randomized, double-blind, placebo-controlled trial. Lancet Neurol, 7(7): 595-604. 3. Trenkwalder, C., Heinig, F. A., Montagna, P., Oertel, W. H., Allen, R. P., Walters, A. S., et al. (2008). A randomized, double-blind, placebo-controlled trial of intravenous suvorelone in restless legs syndrome. Sleep Med.	Richard Allen, PhD Consultant: GSK, Pfizer, UCB, Neurogen Grant/Research Support: GSK Citations: 1. Earley, C. J., Hecker, D., & Allen, R. P. (2005). Repeated brief doses of oral prazosin provide supplemental treatment of restless legs syndrome. Sleep Med, 8(4): 301-306. 2. Earley, C.J., Hecker, D., Horvath A., Barker, P. B., & Allen, R. P. (2004). The treatment of severe restless legs syndrome: a randomized, double-blind, placebo-controlled trial. Lancet Neurol, 7(7): 595-604. 3. Trenkwalder, C., Heinig, F. A., Montagna, P., Oertel, W. H., Allen, R. P., Walters, A. S., et al. (2008). A randomized, double-blind, placebo-controlled trial of intravenous suvorelone in restless legs syndrome. Sleep Med.	Richard Allen, PhD Consultant: GSK, Pfizer, UCB, Neurogen Grant/Research Support: GSK Citations: 1. Earley, C. J., Hecker, D., & Allen, R. P. (2005). Repeated brief doses of oral prazosin provide supplemental treatment of restless legs syndrome. Sleep Med, 8(4): 301-306. 2. Earley, C.J., Hecker, D., Horvath A., Barker, P. B., & Allen, R. P. (2004). The treatment of severe restless legs syndrome: a randomized, double-blind, placebo-controlled trial. Lancet Neurol, 7(7): 595-604. 3. Trenkwalder, C., Heinig, F. A., Montagna, P., Oertel, W. H., Allen, R. P., Walters, A. S., et al. (2008). A randomized, double-blind, placebo-controlled trial of intravenous suvorelone in restless legs syndrome. Sleep Med.	Richard Allen, PhD Consultant: GSK, Pfizer, UCB, Neurogen Grant/Research Support: GSK Citations: 1. Earley, C. J., Hecker, D., & Allen, R. P. (2005). Repeated brief doses of oral prazosin provide supplemental treatment of restless legs syndrome. Sleep Med, 8(4): 301-306. 2. Earley, C.J., Hecker, D., Horvath A., Barker, P. B., & Allen, R. P. (2004). The treatment of severe restless legs syndrome: a randomized, double-blind, placebo-controlled trial. Lancet Neurol, 7(7): 595-604. 3. Trenkwalder, C., Heinig, F. A., Montagna, P., Oertel, W. H., Allen, R. P., Walters, A. S., et al. (2008). A randomized, double-blind, placebo-controlled trial of intravenous suvorelone in restless legs syndrome. Sleep Med.	Richard Allen, PhD Consultant: GSK, Pfizer, UCB, Neurogen Grant/Research Support: GSK Citations: 1. Earley, C. J., Hecker, D., & Allen, R. P. (2005). Repeated brief doses of oral prazosin provide supplemental treatment of restless legs syndrome. Sleep Med, 8(4): 301-306. 2. Earley, C.J., Hecker, D., Horvath A., Barker, P. B., & Allen, R. P. (2004). The treatment of severe restless legs syndrome: a randomized, double-blind, placebo-controlled trial. Lancet Neurol, 7(7): 595-604. 3. Trenkwalder, C., Heinig, F. A., Montagna, P., Oertel, W. H., Allen, R. P., Walters, A. S., et al. (2008). A randomized, double-blind, placebo-controlled trial of intravenous suvorelone in restless legs syndrome. Sleep Med.	Richard Allen, PhD Consultant: GSK, Pfizer, UCB, Neurogen Grant/Research Support: GSK Citations: 1. Earley, C. J., Hecker, D., & Allen, R. P. (2005). Repeated brief doses of oral prazosin provide supplemental treatment of restless legs syndrome. Sleep Med, 8(4): 301-306. 2. Earley, C.J., Hecker, D., Horvath A., Barker, P. B., & Allen, R. P. (2004). The treatment of severe restless legs syndrome: a randomized, double-blind, placebo-controlled trial. Lancet Neurol, 7(7): 595-604. 3. Trenkwalder, C., Heinig, F. A., Montagna, P., Oertel, W. H., Allen, R. P., Walters, A. S., et al. (2008). A randomized, double-blind, placebo-controlled trial of intravenous suvorelone in restless legs syndrome. Sleep Med.	Richard Allen, PhD Consultant: GSK, Pfizer, UCB, Neurogen Grant/Research Support: GSK Citations: 1. Earley, C. J., Hecker, D., & Allen, R. P. (2005). Repeated brief doses of oral prazosin provide supplemental treatment of restless legs syndrome. Sleep Med, 8(4): 301-306. 2. Earley, C.J., Hecker, D., Horvath A., Barker, P. B., & Allen, R. P. (2004). The treatment of severe restless legs syndrome: a randomized, double-blind, placebo-controlled trial. Lancet Neurol, 7(7): 595-604. 3. Trenkwalder, C., Heinig, F. A., Montagna, P., Oertel, W. H., Allen, R. P., Walters, A. S., et al. (2008). A randomized, double-blind, placebo-controlled trial of intravenous suvorelone in restless legs syndrome. Sleep Med.	Richard Allen, PhD Consultant: GSK, Pfizer, UCB, Neurogen Grant/Research Support: GSK Citations: 1. Earley, C. J., Hecker, D., & Allen, R. P. (2005). Repeated brief doses of oral prazosin provide supplemental treatment of restless legs syndrome. Sleep Med, 8(4): 301-306. 2. Earley, C.J., Hecker, D., Horvath A., Barker, P. B., & Allen, R. P. (2004). The treatment of severe restless legs syndrome: a randomized, double-blind, placebo-controlled trial. Lancet Neurol, 7(7): 595-604. 3. Trenkwalder, C., Heinig, F. A., Montagna, P., Oertel, W. H., Allen, R. P., Walters, A. S., et al. (2008). A randomized, double-blind, placebo-controlled trial of intravenous suvorelone in restless legs syndrome. Sleep Med.	Richard Allen, PhD Consultant: GSK, Pfizer, UCB, Neurogen Grant/Research Support: GSK Citations: 1. Earley, C. J., Hecker, D., & Allen, R. P. (2005). Repeated brief doses of oral prazosin provide supplemental treatment of restless legs syndrome. Sleep Med, 8(4): 301-306. 2. Earley, C.J., Hecker, D., Horvath A., Barker, P. B., & Allen, R. P. (2004). The treatment of severe restless legs syndrome: a randomized, double-blind, placebo-controlled trial. Lancet Neurol, 7(7): 595-604. 3. Trenkwalder, C., Heinig, F. A., Montagna, P., Oertel, W. H., Allen, R. P., Walters, A. S., et al. (2008). A randomized, double-blind, placebo-controlled trial of intravenous suvorelone in restless legs syndrome. Sleep Med.	Richard Allen, PhD Consultant: GSK, Pfizer, UCB, Neurogen Grant/Research Support: GSK Citations: 1. Earley, C. J., Hecker, D., & Allen, R. P. (2005). Repeated brief doses of oral prazosin provide supplemental treatment of restless legs syndrome. Sleep Med, 8(4): 301-306. 2. Earley, C.J., Hecker, D., Horvath A., Barker, P. B., & Allen, R. P. (2004). The treatment of severe restless legs syndrome: a randomized, double-blind, placebo-controlled trial. Lancet Neurol, 7(7): 595-604. 3. Trenkwalder, C., Heinig, F. A., Montagna, P., Oertel, W. H., Allen, R. P., Walters, A. S., et al. (2008). A randomized, double-blind, placebo-controlled trial of intravenous suvorelone in restless legs syndrome. Sleep Med.	Richard Allen, PhD Consultant: GSK, Pfizer, UCB, Neurogen Grant/Research Support: GSK Citations: 1. Earley, C. J., Hecker, D., & Allen, R. P. (2005). Repeated brief doses of oral prazosin provide supplemental treatment of restless legs syndrome. Sleep Med, 8(4): 301-306. 2. Earley, C.J., Hecker, D., Horvath A., Barker, P. B., & Allen, R. P. (2004). The treatment of severe restless legs syndrome: a randomized, double-blind, placebo-controlled trial. Lancet Neurol, 7(7): 595-604. 3. Trenkwalder, C., Heinig, F. A., Montagna, P., Oertel, W. H., Allen, R. P., Walters, A. S., et al. (2008). A randomized, double-blind, placebo-controlled trial of intravenous suvorelone in restless legs syndrome. Sleep Med.	Richard Allen, PhD Consultant: GSK, Pfizer, UCB, Neurogen Grant/Research Support: GSK Citations: 1. Earley, C. J., Hecker, D., & Allen, R. P. (2005). Repeated brief doses of oral prazosin provide supplemental treatment of restless legs syndrome. Sleep Med, 8(4): 301-306. 2. Earley, C.J., Hecker, D., Horvath A., Barker, P. B., & Allen, R. P. (2004). The treatment of severe restless legs syndrome: a randomized, double-blind, placebo-controlled trial. Lancet Neurol, 7(7): 595-604. 3. Trenkwalder, C., Heinig, F. A., Montagna, P., Oertel, W. H., Allen, R. P., Walters, A. S., et al. (2008). A randomized, double-blind, placebo-controlled trial of intravenous suvorelone in restless legs syndrome. Sleep Med.	Richard Allen, PhD Consultant: GSK, Pfizer, UCB, Neurogen Grant/Research Support: GSK Citations: 1. Earley, C. J., Hecker, D., & Allen, R. P. (2005). Repeated brief doses of oral prazosin provide supplemental treatment of restless legs syndrome. Sleep Med, 8(4): 301-306. 2. Earley, C.J., Hecker, D., Horvath A., Barker, P. B., & Allen, R. P. (2004). The treatment of severe restless legs syndrome: a randomized, double-blind, placebo-controlled trial. Lancet Neurol, 7(7): 595-604. 3. Trenkwalder, C., Heinig, F. A., Montagna, P., Oertel, W. H., Allen, R. P., Walters, A. S., et al. (2008). A randomized, double-blind, placebo-controlled trial of intravenous suvorelone in restless legs syndrome. Sleep Med.	Richard Allen, PhD Consultant: GSK, Pfizer, UCB, Neurogen Grant/Research Support: GSK Citations: 1. Earley, C. J., Hecker, D., & Allen, R. P. (2005). Repeated brief doses of oral prazosin provide supplemental treatment of restless legs syndrome. Sleep Med, 8(4): 301-306. 2. Earley, C.J., Hecker, D., Horvath A., Barker, P. B., & Allen, R. P. (2004). The treatment of severe restless legs syndrome: a randomized, double-blind, placebo-controlled trial. Lancet Neurol, 7(7): 595-604. 3. Trenkwalder, C., Heinig, F. A., Montagna, P., Oertel, W. H., Allen, R. P., Walters, A. S., et al. (2008). A randomized, double-blind, placebo-controlled trial of intravenous suvorelone in restless legs syndrome. Sleep Med.	Richard Allen, PhD Consultant: GSK, Pfizer, UCB, Neurogen Grant/Research Support: GSK Citations: 1. Earley, C. J., Hecker, D., & Allen, R. P. (2005). Repeated brief doses of oral prazosin provide supplemental treatment of restless legs syndrome. Sleep Med, 8(4): 301-306. 2. Earley, C.J., Hecker, D., Horvath A., Barker, P. B., & Allen, R. P. (2004). The treatment of severe restless legs syndrome: a randomized, double-blind, placebo-controlled trial. Lancet Neurol, 7(7): 595-604. 3. Trenkwalder, C., Heinig, F. A., Montagna, P., Oertel, W. H., Allen, R. P., Walters, A. S., et al. (2008). A randomized, double-blind, placebo-controlled trial of intravenous suvorelone in restless legs syndrome. Sleep Med.	Richard Allen, PhD Consultant: GSK, Pfizer, UCB, Neurogen Grant/Research Support: GSK Citations: 1. Earley, C. J., Hecker, D., & Allen, R. P. (2005). Repeated brief doses of oral prazosin provide supplemental treatment of restless legs syndrome. Sleep Med, 8(4): 301-306. 2. Earley, C.J., Hecker, D., Horvath A., Barker, P. B., & Allen, R. P. (2004). The treatment of severe restless legs syndrome: a randomized, double-blind, placebo-controlled trial. Lancet Neurol, 7(7): 595-604. 3. Trenkwalder, C., Heinig, F. A., Montagna, P., Oertel, W. H., Allen, R. P., Walters, A. S., et al. (2008). A randomized, double-blind, placebo-controlled trial of intravenous suvorelone in restless legs syndrome. Sleep Med.	Richard Allen, PhD Consultant: GSK, Pfizer, UCB, Neurogen Grant/Research Support: GSK Citations: 1. Earley, C. J., Hecker, D., & Allen, R. P. (2005). Repeated brief doses of oral prazosin provide supplemental treatment of restless legs syndrome. Sleep Med, 8(4): 301-306. 2. Earley, C.J., Hecker, D., Horvath A., Barker, P. B., & Allen, R. P. (2004). The treatment of severe restless legs syndrome: a randomized, double-blind, placebo-controlled trial. Lancet Neurol, 7(7): 595-604. 3. Trenkwalder, C., Heinig, F. A., Montagna, P., Oertel, W. H., Allen, R. P., Walters, A. S., et al. (2008). A randomized, double-blind, placebo-controlled trial of intravenous suvorelone in restless legs syndrome. Sleep Med.	Richard Allen, PhD Consultant: GSK, Pfizer, UCB, Neurogen Grant/Research Support: GSK Citations: 1. Earley, C. J., Hecker, D., & Allen, R. P. (2005). Repeated brief doses of oral prazosin provide supplemental treatment of restless legs syndrome. Sleep Med, 8(4): 301-306. 2. Earley, C

S15	Melatonin Treatment of Sleep and Circadian Disorders	Symposium	Alfred Lewy, MD, PhD Consultant: Consultant for Melatonin Agonist Companies Intellectual Property Rights: Co-inventor on Several Melatonin Process Patents Citations: 1. Lewy AJ, Lefler BJ, Emens JS and Baur VK (2006) The circadian basis of winter depression. Proc Natl Acad Sci 103(18): 7144-7419. 2. Lewy AJ, Bauer VK, Cutler NL, Sack RL, Ahmed S, Thomas KH, Blood ML, and Jackson JML (1998) Morning vs evening light treatment of patients with winter depression. Arch Gen Psychiatry 55:890- 896. 3. Lewy A. (2007) Melatonin and human chronobiology. Cold Spring Harbor Symp Quant Biol. 72:626- 636.	Helen Burgess, MD Consultant: Physician's Educational Information Resource Citations: 1. Burgess, et al. (2006) A 3 pulse phase response curve to 3mg of melatonin in humans. J Physiol. 565: 2, 639- 647. 2. Lewy et al. (1998) The human phase response curve (PRC) to melatonin: about 12 at a phase with the PRC to light. Chronobiol. Int. 1998: 15:71-83.	Jonathan Emens, MD Conflicts: None	Kenneth Wright Jr., MD Consultant: Cephalon, Takeda Pharmaceuticals North America, Axon Labs, Novartis Grant/Research Support: Takeda Pharmaceuticals North America Stock/Shareholder: Axon Labs, Inc. Stock Options Citations: 1. Sack R, Auckley D, Auger RR, Carskadon MA, Wright KP Jr., Vitiello M, Zhdanova IV, Circadian Rhythm Sleep Disorders: Part 1. Basic Principles, Shift Work and Jet Lag. An American Academy of Sleep Medicine Review. SLEEP 2007; 30:1456-1479. 2. Wright KP Jr., Rogers NL. Endogenous Versus Exogenous Effects of Melatonin. In SR Pinedi-Renural and DP Cardinali (Eds) Melatonin from Molecules to Therapy. Nova Science Publishers, Inc. Hauppauge, NY 2007; 547- 569.	Dieter Kunz, MD, PhD Speakers' Bureau: Lundbeck, Servier Citations: 1. Mahberg R, Walther S, Kalus P, Bohner G, Haeckel S, Reischies FM, Kuhl KP, Helweg R, Kunz D (2008) Pinealectomy in Alzheimer's disease: An in vivo study using computed tomography. Neurobiol Aging 29:2023-2030. 2. Mahberg R, Haeckel S, Heiderreich JD, Schneitz S, Kunz D. Polysomnographic sleep variables and degree of pineal calcification (DOC) in patients with sleep related disturbances. Sleep Medicine (Epub ahead of print)(PMID: 18755628).
S16	The Use of Complementary and Alternative Medicine for Sleep	Symposium	Norma G. Cutilar, DSN Conflicts: None	Richard R. Bootzin, PhD Conflicts: None	Rachel Marber, PhD Conflicts: None	Sai Bir Khalsa, PhD Conflicts: None	
S17	Trauma, PTSD, and Sleep: Treatments and Health Implications	Symposium	Anne Germain, PhD Conflicts: None	Jack Edinger, PhD Conflicts: None	Christi Ulmer, PhD Conflicts: None	Murray Raskind, MD Conflicts: None	
S18	Apnea Positive Pressure Long-term Efficacy Study (APPLES): Results from the Largest NIH-Sponsored Sleep-Related Clinical Trial	Symposium	Clete A. Kushida, MD, PhD Grant/Research Support: Resprionics, Inc., AERO/Ventus Royalties: Resprionics, Inc. Citations: 1. Kushida CA, Nichols DA, Quan SF, Goodwin JL, White DP, Gottlieb DJ, Walsh JK, Schweitzer PK, Guilleminault C, Simon RD, Leary EB, Hyde PR, Holmes TH, Bloch DA, Green S, McEvoy LK, Geivins A, Dement WC. The Apnea Positive Pressure Long-term Efficacy Study (APPLES): rationale, design, methods, and procedures. J Cin Sleep Med. 2006 Jul 15;2(3):288-300. 2. Kushida CA, Chedak A, Berry RB, Brown LK, Gozal D, Iber C, Pantazisathry S, Quan SF, Rowley JA. Positive Airway Pressure Titration Task Force; American Academy of Sleep Medicine. Clinical guidelines for the manual titration of positive airway pressure in patients with obstructive sleep apnea. J Clin Sleep Med. 2008 Apr 15;4(2):157-71. 3. Kushida CA, Litterer MK, Hirschowitz M, Moryenthaler TI, Alessi CA, Bailey D, Bothecke B, Brown TM, Coleman J Jr, Friedman L, Kaplan S, Kapur VK, Kramer M, Lee-Chiong T, Owens J, Pancer JP, Swick TJ, Wise MG. American Academy of Sleep Medicine. Practice parameters for the use of continuous and bilevel positive airway pressure devices to treat adult patients with sleep-related breathing disorders.	Deborah A. Nichols Conflicts: None	Max Hirschowitz, PhD Grant/Research Support: Resprionics, Inc. Citations: 1. Kushida CA, Nichols DA, Quan SF, Goodwin JL, White DP, Gottlieb DJ, Walsh JK, Schweitzer PK, Guilleminault C, Simon RD, Leary EB, Hyde PR, Holmes TH, Bloch DA, Green S, McEvoy LK, Geivins A, Dement WC. The Apnea Positive Pressure Long-term Efficacy Study (APPLES): rationale, design, methods, and procedures. J Clin Sleep Med. 2006 Jul 15;2(3):288-300. 2. Kushida CA, Chedak A, Berry RB, Brown LK, Gozal D, Iber C, Pantazisathry S, Quan SF, Rowley JA. Positive Airway Pressure Titration Task Force; American Academy of Sleep Medicine. Clinical guidelines for the manual titration of positive airway pressure in patients with obstructive sleep apnea. J Clin Sleep Med. 2008 Apr 15;4(2):157-71. 3. Kushida CA, Litterer MK, Hirschowitz M, Moryenthaler TI, Alessi CA, Bailey D, Bothecke B, Brown TM, Coleman J Jr, Friedman L, Kaplan S, Kapur VK, Kramer M, Lee-Chiong T, Owens J, Pancer JP, Swick TJ, Wise MG. American Academy of Sleep Medicine. Practice parameters for the use of continuous and bilevel positive airway pressure devices to treat adult patients with sleep- related breathing disorders. Sleep. 2006 Mar 1;29(3):378- 387.	Stuart F. Quan, MD Conflicts: None	
S19	Advances in Obesity Hypoventilation Syndrome	Symposium	Babak Mokhlesli, MD Conflicts: None	Amranda J Piper, PhD Grant/Research Support: ResMed Speakers' Bureau: Resprionics, ResMed, Westman Citations: 1. Banerjee D, Yee BJ, Piper AJ, Zwillich CW, Grunstein RR. Obesity Hypoventilation Syndrome. Hypoxemia during continuous positive airway pressure. Chest 2007;131:1678-1684. 2. Piper AJ, Wang D, Yee BJ, Barnes DJ, Grunstein RR. Randomised trial of CPAP vs bilevel support in the treatment of Obesity Hypoventilation Syndrome. Chest 2007;131:1678-1684. 2. Piper AJ, Wang D, Yee BJ, Barnes DJ, Grunstein RR. Randomised trial of CPAP vs bilevel support in the treatment of Obesity Hypoventilation Syndrome without severe nocturnal desaturation. Thorax. 2008;63:395-401. 3. Crumphy F, Piper AJ, Naughton MT. Obesity and the lung 2. Obesity and Sleep disordered breathing. Thorax. 2008;63:738- 46. 4. Norman RG, Scott MA, Ayappa I, Walsleben JA, RAPPORT DM. MD Sleep Continuity Measured by Survival Curve Analysis. Sleep 2006; 29:1625-31. 5. Norman RG, RAPPORT DM, Ayappa I. Detection of flow limitation in obstructive sleep apnea with an artificial neural network. Physiol Meas 2007; 28:1-12. 6. Berger KI, Norman RG, Ayappa I, Oppenheimer BW, RAPPORT DM, Goldring RB. Potential mechanism for transition between acute hypercapnia during sleep to chronic hypercapnia during wakefulness in obstructive sleep apnea. Adv Exp Med Biol 2008; 605:431-436.	Elis Katarz, MD Conflicts: None	Carole Marcus, MBChB Conflicts: None	Alman Tulaimat, MD Conflicts: None
S20	Pediatric OSA and Arousal - Cortical Versus Autonomic Arousal and Potential Implications	Symposium	Colin Sullivan, PhD Conflicts: None	Elis Katarz, MD Conflicts: None	Carole Marcus, MBChB Conflicts: None	David Gozal, MD Conflicts: None	
S21	New Insights into the Role of the Basal Forebrain in Cortical Activation	Symposium	Patrick Fuller, PhD Conflicts: None	Barbara Jones, PhD Conflicts: None	Ritche Brown, PhD Conflicts: None	Robert McCarley, MD Conflicts: None	
S22	Sleep and Hypertension Does Sleep Have a Universal Vital Function Across Individuals and Species	Symposium	Antonio Culebras, MD Speakers' Bureau: Boehringer-Ingelheim Citations: 1. Culebras A. Blood pressure changes in sleep, sleep apnea and stroke. Int J Stroke 2006;3 (Suppl. 1):34. 2. Somers VK, White DP, Amin R, Abraham WT, Costa F, Culebras A, Daniels S, Floras JS, Hunt CE, Olson LJ, Pickering TG, Russell R, Vito M, Young T. Sleep Apnea and Cardiovascular Disease. An American Heart Association/American College of Cardiology Scientific Statement From the American Heart Association High Blood Pressure Research Council Professional Education Committee, Clinical Cardiology Council, Stroke Council, and Cardiovascular Nursing Council. In Collaboration With the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health). Circulation 2008; 118:100-119. 3. Culebras A. Sleep apnea and stroke. Rev Neurol Dis. 2005;2:13-19.	Virend K Somers, MBChB, PhD Consultant: Resprionics, ResMed, Glaxo Smith Kline, Sepracor Citations: 1. Somers VK, White DP, Amin R, Abraham WT, Costa F, Culebras A, Daniels S, Floras JS, Hunt CE, Olson LJ, Pickering TG, Russell R, Woo M, Young T. Sleep Apnea and Cardiovascular Disease. An American Heart Association/American College of Cardiology Scientific Statement From the American Heart Association High Blood Pressure Research Council Professional Education Committee, Clinical Cardiology Council, Stroke Council, and Cardiovascular Nursing Council. In Collaboration With the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health). Circulation 2008; 118:100-119. 3. Culebras A. Sleep apnea and stroke. Rev Neurol Dis. 2005;2:13-19.	David Dinges, PhD Conflicts: None	Clete Kushida, MD, PhD, RPSGT Conflicts: None	Jacques Montplaisir, MD, PhD Grant/Research Support: Boehringer-Ingelheim, sanofi- aventis, GlaxoSmithKline Consultant: sanofi-aventis, Boehringer-Ingelheim, Jazz Pharmaceuticals, Servier Citations: 1. Pennessi MR, Montplaisir J, Colombo R, Lavigne G, Lantieri PA. Nocturnal blood pressure changes in patients with restless legs syndrome. Neurology. 2007 Apr 10;68(15):1213-8. 2. Montplaisir J. Abnormal motor behavior during sleep. Sleep Med. 2004 Jun;5 (Suppl 1):S31-4. Review.
S23		Symposium	Jerome Siegel, PhD Conflicts: None	Sean P. A. Drummond, PhD Consultant: Actelion, Inc. Grant/Research Support: Cephalon, Inc. Citations: 1. McKenna, B.S., D.L. Dickinson, H.J. Orr, and S.P.A. Drummond. The Effects of 24 Hours of Sleep Deprivation on Risky and Ambiguous Decision Making. Journal of Sleep Research. 2007. 16: p. 245-252. 2. Dickinson, D.L., and S.P.A. Drummond. The Effects of Total Sleep Deprivation on Bayesian Updating, Judgment and Decision Making. 2008. 3(2): p. 181-190.	William D. S. Killgore, PhD Conflicts: None	David L. Dickinson, PhD Conflicts: None	
S24	Making Decisions while Sleep Deprived: Caveat Emptor	Symposium	Michael Chae, MBBS Conflicts: None	Michael Chae, MBBS Conflicts: None	William D. S. Killgore, PhD Conflicts: None	David L. Dickinson, PhD Conflicts: None	
S25	Seizing the Event: The Sleeping Epileptic Child	Symposium	Henry Atarhan, MD Conflicts: None	Henry Atarhan, MD Conflicts: None	Oscar Craculovic, MD Conflicts: None	Sergey V. Kozhik, MD Conflicts: None	
S26	Neuropsychiatric Comorbidities of Obstructive Sleep Apnea Syndrome	Symposium	Ellemargi Altens Conflicts: None	Ellemargi Altens Conflicts: None	Joel Dimsdale, PhD Conflicts: None	Dawn Brown, MD Conflicts: None	
S27	Brain Imaging of Insomnia: Hyperarousal, Hypoactivation or Compensatory Mechanisms?	Symposium	Howard Roffwarg, MD Conflicts: None	Howard Roffwarg, MD Conflicts: None	Ceyne Bastien, PhD Conflicts: None	Dieter Riemann, MD, PhD Conflicts: None	
I01	Participation of REM Sleep in the Development of the Brain: Starting Hypothesis, Unfolding Data, Current Perspective	Keynote Address	Thomas Balkin, PhD Conflicts: None	Thomas Balkin, PhD Conflicts: None	Philip Haydon, PhD Conflicts: None		
I02	Science for the Sleep Soldier	Invited Lecturer	Philip Haydon, PhD Conflicts: None	Philip Haydon, PhD Conflicts: None			
I03	Glut Modulation of Sleep	Invited Lecturer	Sigrid Vaseley, MD Consultant: Gallien, Johnson & Johnson Pharmaceuticals Citations: Consultant twice for Gallien Pharmaceuticals; Consultant once for BTG/Johnson & Johnson Citations: 1. Vaseley S. J Appl Physiol 2009;66(1):3-4. 2. Zhu Y, Fenik P, Zhan G, et al. J Neurosci 2007;27(37):10060-71. 3. Conduch R, Saito A, Hodgson W, et al. Sleep Med Rev 2007;11(5):361-75.	Michael Chae, MBBS Conflicts: None	William D. S. Killgore, PhD Conflicts: None	David L. Dickinson, PhD Conflicts: None	
I04	Neural Injury in Sleep Apnea: Fixing What You Can Patient by Patient	Invited Lecturer	Anne Germain, PhD Conflicts: None	Anne Germain, PhD Conflicts: None			
I05	Sleep in Posttraumatic Stress Disorder	Invited Lecturer	Barbara Jones, PhD Conflicts: None	Barbara Jones, PhD Conflicts: None			
I06	Neurotransmitters, Organization and Activity of Sleep-wake Neural Systems	Invited Lecturer	Ronald Chervin, MD Consultant: Resprionics, Inc. Stock/Shareholder: Pavod Medical, Inc. Intellectual Property Rights: University of Michigan employer owns a patent and provisional patent on two signal analysis algorithms invented in part by speaker Citations: 1. Chervin, RD, Burns JW, Ruzicka DL. Electroencephalographic changes during respiratory cycles predict sleepiness in sleep apnea. Am J Respir Crit Care Med 2005; 171:652-658. 2. Chervin RD, Mahora RK, Burns JW. Respiratory cycle-related EEG changes during sleep reflect respiratory pressures. Sleep (in press). 3. Burns JW, Corcoss F, Little RJ, Argall NJ, Gilman S, Chervin RD. EMG variance during polysomnography as an assessment for REM sleep behavior disorder. Sleep 2007; 30:1771-1778.	Sean Drummond, PhD Conflicts: None	Chiara Cirelli, MD, PhD Conflicts: None		
I07	Polysomnography: What Does It Accomplish and How Can We Make It Better?	Invited Lecturer	Anne Germain, PhD Conflicts: None	Anne Germain, PhD Conflicts: None			
I08	What Does Circadian Complexity Imply about the Regulation of Sleep?	Invited Lecturer	Michael Menaker, PhD Conflicts: None	Michael Menaker, PhD Conflicts: None			
I09	Improving Treatments for Chronic Insomnia and Sleep Disturbance in Bipolar Disorder	Invited Lecturer	Allison Harvey, PhD Consultant: Actelion Citations: 1. Harvey AG. (2008) Sleep and Circadian Rhythms in Bipolar Disorder: Seeking synchrony, harmony and regulation. American Journal of Psychiatry, 165, 820-829. 2. Harvey AG, Talbot LS & Gerber A. (in press). Sleep Disturbance in Bipolar Disorder Across the Lifespan. Clinical Psychology: Science and Practice. 3. Harvey AG, McClintock E & Gruber J (in press). Toward an Effective Science of Insomnia Treatments. In A. King & D. Sloan (Eds). Emotion Regulation and Psychopathology. OUP.	Allison Harvey, PhD Conflicts: None			
I10	Neurobiology of Narcolepsy: What Sleep Mice can Teach Us about Sleep People	Invited Lecturer	Thomas Scammell, MD Consultant: Roche, Merck, GlaxoSmithKline, Actelion Speakers' Bureau: Jazz Pharmaceuticals Citations: 1. Narcolepsy with Cataplexy. Davilliers, Arnulf, Mignot. Lancet 2007;369: 899-911. 2. To Eat or To Sleep? Orexin in the Regulation of Feeding and Wakefulness. Willie, Chermelli, Sinton, Tangarova. Ann Rev Neurosci; 24: 429- 2001. 3. Behavioral State Instability in Orexin Knockout Mice. Mochizuki, et al. 2004 J Neurosci 24:6291-6300.	Thomas Scammell, MD Conflicts: None			
M01	Treatment of Insomnia in General Medicine	Meet the Professor	Colin Espie, PhD Consultant: Sanofi-Aventis, GSK, and Actelion Speakers' Bureau: Takeda and Lundbeck Citations: 1. Morin CM, Bootzin RR, Buysse DJ, Edinger JD, Espie CA and Lichstein KL. (2006) Psychological and behavioral treatment of insomnia. Update of the recent evidence (1998-2004) prepared by a Task Force of the American Academy of Sleep Medicine. Sleep 29: 1386-1414. 2. Morin CM and Espie CA. (2003) Insomnia: A Clinical Guide to Assessment and Treatment. Kluwer Academic/Plenum Publishers, New York (ISBN 0-306-47750- 5). 3. Espie CA, MacMahon KMA, Kelly H-L, Broomfield NM, Douglas NJ, Engelman HE, McKinstry B, Morin CM, Walker A and Wilson P. (2007) Randomised clinical effectiveness trial of nurse-administered small group CBT for persistent insomnia in general practice. SLEEP 30, 574-584.	Colin Espie, PhD Conflicts: None			
M02	Surgical Management of Sleep Apnea	Meet the Professor	Aaron Siver, MD Conflicts: None	Aaron Siver, MD Conflicts: None			

R02	Research Grant Workshop: Do's and Don'ts from Grant Writing to the Grant Review Process	Grantsmanship/Research Opportunities Session	Phyllis Zee, MD, PhD Conflicts: None	Robert Greene, MD, PhD Conflicts: None	Janet Mullington, PhD Conflicts: None	Gary Richardson, MD Consultant: Takeda Pharmaceuticals, sanofi-aventis, Jazz Speaker's Bureau: Takeda Pharmaceuticals, sanofi-aventis Citations: 1. Knutson KL, Spiegel K, Penzel P, Van Cauter E. The metabolic consequences of sleep deprivation. Sleep Med Rev. 2007 Jun;11(3):163-78. 2. Reiter RJ. Melatonin: clinical relevance. Best Pract Res Clin Endocrinol Metab. 2003 Jun;17(2):273-85. 3. Boyer R, Finkelstein J, Roffwarg H, Kaplan S, Weitzman E, Hellman L. Synchronization of augmented luteinizing hormone secretion with sleep during puberty. N Engl J Med. 1972;287(12):582-6.						
R03	Beyond the NIH: Diversifying Your Research Funding Sources	Grantsmanship/Research Opportunities Session	James Walsh, PhD Research/Grant Support: Pfizer, Merck & Co, Somaxon, Evotec, Actelion, Vanda, Neurogen, sanofi-aventis, Ventus, Respiroics, Jazz Pharmaceuticals Consultant: Pfizer, sanofi-aventis, Cephalon, Schering-Plough/Organon, Neurocrine, Takeda America, Actelion, Sepracor, Jazz, Respiroics, Transcept, Neurogen, GlaxoSmithKline, Somaxon, Eli Lilly, Evotec, Merck, Kingstree, Vanda, Ventus, Sonoma Citations: 1. Walsh JK, Randazzo AC, Stone K, Eisenstein R, Feren SD, Kaly S, Dickey P, Roelofs T, Ruth T, Schweitzer PK. Tiagabine is associated with sustained attention during sleep restriction: evidence for the value of slow wave sleep enhancement? Sleep. 2008; 29: 433-443. 2. Walsh JK, Snyder E, Hall J, Randazzo AC, Griffin K, Groeger J, Eisenstein R, Feren SD, Dickey P, Schweitzer PK. Slow wave sleep enhancement with gaboxadol reduces daytime sleepiness during sleep restriction. Sleep. 2008;69:672.	Terri Weaver, PhD, RN Research/Grant Support: Respiroics, Inc., Protech, Respiroics Respiratory and Sleep Research Foundation Consultant: Apex Medical, Inc., Cephalon, Inc. FOSO License Agreements: sanofi-aventis, Merck & Co., Inc., Sleep Solutions, N.V., Organon, Apex Medical, Inc., Ventus Medical, GlaxoSmithKline Citations: 1. Clary D. Science. 2009 March 13;323(5920):1413. 2. Sunders CA, Baska CW. Funding opportunities for investigators in the early stages of career development.	Janet Croft, PhD Conflicts: None	Charles Amlaner, DPhil Conflicts: None	David Dirges, PhD Consultant: Sanofi-Aventis, Merck, Cephalon, Johnson & Johnson, Lilly, Mars Grant/Research Support: NIH, NASA, NSBRI, AFOSR, DHS, Merck, Johnson & Johnson Citations: Conflicts are not relevant to presentation.				Max Hirschowitz, PhD Conflicts: None	